BPC-157 Protects the Stomach From Damage Caused by the Diabetes Drug Alloxan
BPC-157 significantly reduced and accelerated healing of stomach ulcers caused by alloxan (a diabetogenic agent) in both rats and mice, with effects lasting throughout the observation period.
Quick Facts
What This Study Found
BPC-157 significantly attenuated alloxan-induced gastric lesions in rats (200 mg/kg SC) and mice (400 mg/kg IP), reducing lesion severity and accelerating healing over the observation period.
Key Numbers
How They Did This
Animal study in rats and mice. Alloxan was administered to induce gastric lesions and diabetes. BPC-157 was given IP. Gastric lesions were scored at 24 hours and later timepoints.
Why This Research Matters
Diabetic patients often develop gastropathy (stomach problems). A peptide that protects the stomach from chemical-induced damage relevant to diabetes could have therapeutic applications for diabetic gastrointestinal complications.
The Bigger Picture
BPC-157's gastroprotective effects extend beyond simple ulcer healing to protecting against chemical toxicity. This broadens its potential applications to medication-induced and disease-related stomach damage.
What This Study Doesn't Tell Us
Animal study using alloxan, which is not used clinically and may not perfectly model diabetic gastropathy. The mechanism of gastroprotection was not elucidated.
Questions This Raises
- ?Does BPC-157 protect against other medication-induced gastropathy?
- ?Could BPC-157 help diabetic patients with gastric complications?
- ?What is BPC-157's mechanism of gastroprotection against chemical agents?
Trust & Context
- Key Stat:
- Both species protected BPC-157 reduced alloxan-induced gastric lesions in both rats and mice, showing consistent gastroprotection across species
- Evidence Grade:
- Preliminary animal evidence in two species showing consistent gastroprotective effects, but limited by the alloxan model's clinical relevance.
- Study Age:
- Published in 1999. BPC-157's gastroprotective effects have been further documented across numerous insult models.
- Original Title:
- Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice.
- Published In:
- Journal of physiology, Paris, 93(6), 501-4 (1999)
- Authors:
- Petek, M(28), Sikiric, P(36), Anic, T(17), Buljat, G, Separovic, J, Stancic-Rokotov, D, Seiwerth, S, Grabarevic, Z, Rucman, R, Mikus, D, Zoricic, I, Prkacin, I, Sebecic, B, Ziger, T, Coric, V, Turkovic, B, Aralica, G, Rotkvic, I, Mise, S, Hahn, V
- Database ID:
- RPEP-00551
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is BPC-157's gastroprotective effect?
BPC-157, derived from a stomach protein, has been shown to protect the stomach lining from damage caused by various agents. In this study, it protected against chemical damage from alloxan, a substance that also induces diabetes.
Is this relevant to diabetes?
Potentially. Diabetic patients often develop stomach problems. If BPC-157 can protect the stomach from diabetes-related damage (not just alloxan-specific damage), it could help manage diabetic gastrointestinal complications.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00551APA
Petek, M; Sikiric, P; Anic, T; Buljat, G; Separovic, J; Stancic-Rokotov, D; Seiwerth, S; Grabarevic, Z; Rucman, R; Mikus, D; Zoricic, I; Prkacin, I; Sebecic, B; Ziger, T; Coric, V; Turkovic, B; Aralica, G; Rotkvic, I; Mise, S; Hahn, V. (1999). Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice.. Journal of physiology, Paris, 93(6), 501-4.
MLA
Petek, M, et al. "Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice.." Journal of physiology, 1999.
RethinkPeptides
RethinkPeptides Research Database. "Pentadecapeptide BPC 157 attenuates gastric lesions induced ..." RPEP-00551. Retrieved from https://rethinkpeptides.com/research/petek-1999-pentadecapeptide-bpc-157-attenuates
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.